Brief: Transgene New Data Shows Cancer Vaccine Candidate Induced Strong And Specific Immune Responses Against Tumors

Transgene SA

18/04/2023 07:55

April 18 (Reuters) - Transgene SA  TRNG.PA :
    * NEW DATA SHOWING THAT TRANSGENE AND NEC’S INDIVIDUALIZED
CANCER
VACCINE TG4050 INDUCES STRONG AND SPECIFIC IMMUNE RESPONSES
AGAINST TUMORS PRESENTED AT AACR 2023
    * IN HEAD AND NECK CANCER TRIAL TO DATE, ALL PATIENTS
TREATED WITH
TG4050 HAVE REMAINED DISEASE-FREE, DESPITE UNFAVORABLE SYSTEMIC
IMMUNITY AND TUMOR MICRO-ENVIRONMENT BEFORE TREATMENT
    * NEW PHASE I DATA CONFIRM PROMISING IMMUNOGENICITY AND
EFFICACY
PROFILE OF TG4050, AN INDIVIDUALIZED NEOANTIGEN CANCER VACCINE
DEVELOPED BY TRANSGENE IN COLLABORATION WITH NEC CORPORATION
    * TRANSGENE AND NEC ARE CONSIDERING MOST APPROPRIATE PATH
TOWARDS
REGISTRATION IN HEAD AND NECK, WITH A PHASE II TRIAL TO BE
INITIATED IN H2 2023
    * CEO: WE ARE PREPARING FOR A PHASE II TRIAL AS PART OF
REGISTRATION PATH, WHICH COULD START AS EARLY AS SECOND HALF OF
2023 FOR HEAD AND NECK CANCER
    * EXPECTS LAST PATIENT TO BE TREATED IN COMING WEEKS
    * FINAL RESULTS FROM THIS TRIAL ARE EXPECTED IN MID-2024
    * TO DATE, VACCINE HAS BEEN WELL TOLERATED AND NO RELATED
SERIOUS
ADVERSE EVENTS HAVE BEEN REPORTED

Source text for Eikon:  ID:nBw90X51Fa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))